{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:58:40Z","timestamp":1785308320538,"version":"3.55.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The efficacy of cellular therapies has been demonstrated in hematologic malignancies, and their use is expanding to solid tumors. Predictors of outcomes and toxicities remain limited in patients undergoing cellular therapies for solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data on patients with solid tumors who received cellular therapies between January 2016 and July 2025 in the Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) at The University of Texas MD Anderson Cancer Center were reviewed retrospectively using the institutional CHIMERA database platform.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 122 patients, increased baseline C-reactive protein (CRP) was associated with shorter overall survival (OS) (hazard ratio [HR] 1.009, 95% confidence interval (CI) 1.005\u20131.013; P &amp;lt; 0.001), and higher log-transformed cell dose was associated with longer progression-free survival (PFS) (HR 0.636, 95% CI 0.476\u20130.850; P\u00a0=\u00a00.002). Among patients with baseline pulmonary function testing, zDLCO was associated with OS (HR 0.794, 95% CI 0.674-0.936; P\u00a0=\u00a00.006) and PFS (HR 0.826, 95% CI 0.696-0.979; P\u00a0=\u00a00.028). Cytokine release syndrome (CRS) occurred in 70 participants (57.4%). In the multivariate analysis, lower baseline absolute neutrophil count was associated with CRS of any grade (odds ratio [OR] 0.594, 95% CI 0.376-0.939; P\u00a0=\u00a00.026) and with CRS grade 2 or higher (OR 0.470, 95% CI 0.252-0.877; P\u00a0=\u00a00.018). Immune effector cell-associated neurotoxicity syndrome developed in 11 patients (9.0%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Baseline parameters such as CRP and pulmonary function may help identify patients at higher risk of adverse outcomes and toxicity during cellular therapy for solid tumors, and warrant prospective evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1848516","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:58:50Z","timestamp":1785304730000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical determinants of survival outcomes and acute toxicity after adoptive cellular therapy for solid tumors"],"prefix":"10.3389","volume":"17","author":[{"given":"Jeong Uk","family":"Lim","sequence":"first","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]},{"name":"Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick","family":"Tao","sequence":"additional","affiliation":[{"name":"Melanoma & Skin Cancer Center, Division of Hematology\/Oncology, Department of Medicine, University of California, San Francisco","place":["San Francisco, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Nevins","family":"Selvadurai","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ecaterina Elena","family":"Dumbrava","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Champiat","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Mirallas","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolia Maria","family":"Tsimberidou","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi Rodon","family":"Ahnert","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina A.","family":"Piha-Paul","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Yap","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tin-Yun","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Sheshadri","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.927153","article-title":"CAR-T cell therapy in hematological Malignancies: Current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B8","unstructured":"Iovance\u2019s AMTAGVI\u2122 (lifileucel) receives U.S. FDA accelerated approval for advanced melanoma\n          \n          2024"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: Phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.713577","article-title":"Tumor burden measured by 18F-FDG PET\/CT in predicting efficacy and adverse effects of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphoma","volume":"11","author":"Hong","year":"2021","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009309","article-title":"A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma","volume":"7","author":"Shouse","year":"2023","journal-title":"Blood Adv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1378944","article-title":"Biomarkers for prediction of CAR T therapy outcomes: Current and future perspectives","volume":"15","author":"Levstek","year":"2024","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200502-212OC","article-title":"Pretransplant lung function, respiratory failure, and mortality after stem cell transplantation","volume":"172","author":"Parimon","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.01.019","article-title":"Role of pulmonary function tests to predict complications after chimeric antigen receptor T-cell therapy","volume":"25","author":"Walder","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1164\/rccm.202303-0613OC","article-title":"Application of Global Lung Function Initiative global spirometry reference equations across a large, multicenter pulmonary function lab population","volume":"209","author":"Kanj","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1700010","DOI":"10.1183\/13993003.00010-2017","article-title":"Official ERS technical standards: Global Lung Function Initiative reference values for the carbon monoxide transfer factor for Caucasians","volume":"50","author":"Stanojevic","year":"2017","journal-title":"Eur Respir J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30472-1","article-title":"Standardisation of lung function test interpretation: Global Lung Function Initiative","volume":"6","author":"Stanojevic","year":"2018","journal-title":"Lancet Respir Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2101499","DOI":"10.1183\/13993003.01499-2021","article-title":"ERS\/ATS technical standard on interpretive strategies for routine lung function tests","volume":"60","author":"Stanojevic","year":"2022","journal-title":"Eur Respir J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.11.025","article-title":"Pulmonary symptoms measured by the National Institutes of Health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease","volume":"20","author":"Palmer","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4708","DOI":"10.1182\/blood-2024-203984","article-title":"An endothelial activation and stress index (EASIX) based predictive model for neurotoxicity and cytokine release syndrome (CRS) after B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory multiple myeloma (RRMM)","volume":"144","author":"Goel","year":"2024","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023990","article-title":"Association of pulmonary function with late-life cardiac function and heart failure risk: The ARIC study","volume":"11","author":"Ramalho","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/resp.70103","article-title":"Management of COPD with cardiovascular risk in Asia: A review by the Asian Pacific Society of Respirology COPD Assembly","volume":"30","author":"Rhee","year":"2025","journal-title":"Respirology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.6.1952","article-title":"The relationship between reduced lung function and cardiovascular mortality: A population-based study and a systematic review of the literature","volume":"127","author":"Sin","year":"2005","journal-title":"Chest"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1378\/chest.118.3.656","article-title":"Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study","volume":"118","author":"Schunemann","year":"2000","journal-title":"Chest"},{"key":"B28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jtct.2023.12.010","article-title":"Simple score of albumin and CRP predicts high-grade toxicity in patients with multiple myeloma receiving CAR-T therapy","volume":"30","author":"Akhtar","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.879608","article-title":"Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy","volume":"13","author":"Sterner","year":"2022","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.05.004","article-title":"Severity of cytokine release syndrome influences outcome after axicabtagene ciloleucel for large B cell lymphoma: Results from the US Lymphoma CAR-T Consortium","volume":"22","author":"Jacobs","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713469","article-title":"Neutrophils and the systemic inflammatory response syndrome (SIRS)","volume":"24","author":"Sikora","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007246","article-title":"Higher doses of tisagenlecleucel are associated with improved outcomes: A report from the pediatric real-world CAR consortium","volume":"7","author":"Stefanski","year":"2023","journal-title":"Blood Adv"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014488","article-title":"Pretreatment pulmonary function testing has limited utility in B-cell lymphoma treated with CD19 CAR T cells","volume":"9","author":"Sdayoor","year":"2025","journal-title":"Blood Adv"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1848516\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:58:51Z","timestamp":1785304731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1848516\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2026.1848516"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1848516","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1848516"}}